

Disclosures

Personal Commercial (6)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Bristol-Myers Squibb	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Bristol-Myers Squibb Company	Other - Chair, Events Adjudication Committee for trial of apixiban in children with leukemia/lymphoma and indwelling lines, in contract with Boston Children's Hospital	None (\$0)	Congenital Heart Disease and Pediatric Cardiology Other
Daiichi Sankyo	Consultant Fees/Honoraria	Modest (< \$5,000)	Congenital Heart Disease and Pediatric Cardiology
Pfizer	Research/Research Grants	Significant (>= \$5,000)	Other
Pfizer Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Pfizer Inc	Other - PI of Clinical Event Adjudication Committee through grant to Boston Children's Hospital	Significant (>= \$5,000)	Congenital Heart Disease and Pediatric Cardiology

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Centers for Disease Control	Research/Research Grants	Significant (>= \$5,000)	Other
Department of Defense	Research/Research Grants	Significant (>= \$5,000)	Congenital Heart Disease and Pediatric Cardiology
NIH, NHLBI † NHLBI	Research/Research Grants	Significant (>= \$5,000)	Congenital Heart Disease and Pediatric Cardiology

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/9/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/9/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/9/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/9/2023

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.